Kaplan–Meier survival analysis revealed that patients with MM with high MUC20 expression had longer median progression-free survival (PFS) and overall survival (OS) than those with low MUC20 expression after PI treatment (Fig. 2B). The gene discussed is MUC20; the disease is Miyoshi myopathy.